Press Release

Back to Press Release List

KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine

– Posters at AACR-NCI-EORTC and SITC illustrate genome-wide, in vivo T-cell approach to identify and validate novel therapeutic immuno-oncology targets –

CAMBRIDGE, Mass., October 28, 2019 – KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug development, today announced two upcoming presentations at leading scientific immuno-oncology congresses. The data demonstrate the capabilities of the company’s proprietary CRISPRomics® discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery.

“There is a significant need for next-generation immuno-oncology therapies as the majority of cancer patients today experience an insufficient response to PD-1/PD-L1 therapies. The data we will be sharing demonstrate the potential of our CRISPRomics discovery platform to systematically identify and validate new cancer therapies for patients with PD-1 refractory solid tumors,” said Frank Stegmeier, Ph.D., Chief Scientific Officer at KSQ Therapeutics. “KSQ was founded on the premise that CRISPR-enabled functional genomics can improve on current approaches to drug discovery and, taken together, these poster presentations describing the output of our genome-scale in vivo T-cell screens show that our platform can do this with a high degree of precision and quality, pointing the direction towards promising avenues of drug development.”

Presentations include:

  • At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Comprehensive identification of novel therapeutic targets for treatment of PD-1 resistant solid tumors via a genome-scale CRISPR/Cas9 in vivo T-cell screen – Poster # C101 – Tuesday, October 29 – 3:30-4:00 p.m. – Level 2 Hall D
  • At the Society for Immunotherapy of Cancer’s 34th Annual Meeting: An immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets – Poster # P550 – Saturday, November 9 – 12:35 – 2:05 p.m. and 7:00-8:35 p.m.

About KSQ Therapeutics

KSQ Therapeutics is using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug development. The company is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer, across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company’s website at www.ksqtx.com.

KSQ Contact:
Michael Lampe
Tel: 484-575-5040
michael@scientpr.com